TREA

90574267 - LATTICE

Follow

Information

  • Trademark
  • 90574267
  • Serial Number
    90574267
  • Filing Date
    March 11, 2021
    3 years ago
  • Transaction Date
    March 25, 2024
    6 months ago
  • Status Date
    March 25, 2024
    6 months ago
  • Published for Opposition Date
    June 28, 2022
    2 years ago
  • Location Date
    August 23, 2022
    2 years ago
  • Status Code
    606
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    IN, SUNG HYUN
  • Attorney Docket Number
    106517999100
    Attorney Name
    Carrie L. Kiedrowski
    Law Office Assigned Location Code
    L30
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
LATTICE
Case File Statements
  • GS0441: Providing genomic, imaging and pathology data being medical information and medical analyses based on collected clinical and research information in the field of cancer and other diseases for medical purposes; analysis of cells, tissues, gene expressions, gene sequences, genome annotation, transcriptome characterization, and genome mapping for medical diagnosis and treatment of cancer, neurological disease, respiratory disease, inflammatory disease, and mitochondrial disease; preparation of reports relating to gene expressions, gene and genome sequences, genome interaction and annotation, transcriptome analysis and characterization, and genome mapping for medical diagnosis and treatment of cancer, neurological disease, respiratory disease, inflammatory disease, and mitochondrial disease; medical assistance services in the nature of genetic and medical information provided to medical professionals from remote locations via the internet and global computer networks through the use of archived genome sequence information, medical images, diagnostic test results, and a data storage and retrieval system; medical genetic testing consultations provided via phone, online chat or videoconferencing; medical diagnostic testing, monitoring and reporting services; medical imaging services; medical information; medical screening; medical testing for diagnostic purposes; multi-disciplinary, integrative, genetic consultations for medical treatment purposes; providing a website featuring genetic and medical information; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via electronic patient monitoring devices that feed information to the website that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions; providing medical profiles and medical record analysis and assessments via a website that are designed to provide custom tailored outputs about recommended resources and treatments associated with a defined set of symptoms, concerns, genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; providing medical testing and medical consultations to individuals and their physicians to help them make health, wellness and nutritional changes in their daily living to improve health; providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms based on genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; provision of health care and medical services by health care professionals via the internet or telecommunication networks; remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes; health assessment services, namely, providing assessment of risk of disease and providing health monitoring of individuals all through use of genome sequencing analysis and reporting, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; all for medical treatment and diagnostic purposes
  • GS0421: Consulting services relating to scientific and medical research concerning genomic, imaging, pathology and clinical data; designing clinical trials or studies, enriching and enhancing clinical trial or study designs in the nature of research and development in the field of medicine; clinical research in the fields of de-risking clinical trial or study designs, clinical trials simulations and clinical endpoint selection; clinical research, namely, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic, imaging, pathology and clinical data; medical and scientific research, namely, conducting laboratory testing for clinical trials of pharmaceuticals and medical devices in humans; health care services, namely, medical laboratory services and clinical scientific laboratory services for testing clinical specimens for the purpose of providing information for medical research, clinical trials, and pre-clinical investigations; clinical research in the fields of patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses; clinical research, namely, accessing and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; consulting, consultancy, and consulting services related to clinical trials or studies, namely, designing clinical trials or studies, enriching and enhancing clinical trial or study designs in the nature of research and development in the field of medicine, de-risking clinical trial or study designs, conducting clinical trials simulations, clinical endpoint selection, analyzing preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; consulting, consultancy, and consulting services related to clinical trials or studies, namely, conducting patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination; conducting drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses in the nature of medical research, and pharmaceutical development, in the fields of omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, all related to the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; medical research in the nature of disease diagnoses and treatment determination, selection, and identification of cells, proteins, small molecules, and nucleotides in a sample for scientific, research, and technological purposes, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and services all in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation for others
Case File Event Statements
  • 3/25/2024 - 6 months ago
    33 - ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Type: MAB6
  • 3/25/2024 - 6 months ago
    32 - ABANDONMENT - NO USE STATEMENT FILED Type: ABN6
  • 10/26/2023 - 11 months ago
    31 - ASSIGNED TO EXAMINER Type: DOCK
  • 6/15/2023 - a year ago
    30 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 6/13/2023 - a year ago
    29 - SOU EXTENSION 2 GRANTED Type: EX2G
  • 6/13/2023 - a year ago
    28 - SOU EXTENSION 2 FILED Type: EXT2
  • 6/13/2023 - a year ago
    27 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 1/26/2023 - a year ago
    26 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 1/24/2023 - a year ago
    25 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 1/24/2023 - a year ago
    24 - SOU EXTENSION 1 FILED Type: EXT1
  • 1/24/2023 - a year ago
    23 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 8/23/2022 - 2 years ago
    22 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 6/28/2022 - 2 years ago
    21 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 6/28/2022 - 2 years ago
    20 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 6/23/2022 - 2 years ago
    19 - ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Type: ASCK
  • 6/8/2022 - 2 years ago
    18 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 5/25/2022 - 2 years ago
    17 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 5/25/2022 - 2 years ago
    16 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 5/25/2022 - 2 years ago
    15 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 5/25/2022 - 2 years ago
    14 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 5/25/2022 - 2 years ago
    13 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 5/9/2022 - 2 years ago
    12 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 5/9/2022 - 2 years ago
    11 - FINAL REFUSAL E-MAILED Type: GNFR
  • 5/9/2022 - 2 years ago
    10 - FINAL REFUSAL WRITTEN Type: CNFR
  • 4/5/2022 - 2 years ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 4/4/2022 - 2 years ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/4/2022 - 2 years ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 10/7/2021 - 2 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 10/7/2021 - 2 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 10/7/2021 - 2 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 10/6/2021 - 2 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 6/11/2021 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 3/15/2021 - 3 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP